Loading...
XSHE
002038
Market cap1.15bUSD
Dec 05, Last price  
7.89CNY
1D
-1.13%
1Q
3.00%
Jan 2017
-55.70%
IPO
798.73%
Name

Beijing SL Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002038 chart
P/E
P/S
12.27
EPS
Div Yield, %
1.90%
Shrs. gr., 5y
0.43%
Rev. gr., 5y
-20.11%
Revenues
660m
-35.15%
118,557,674143,936,377237,530,969358,002,928390,024,556457,842,025622,772,1651,007,017,7821,161,778,7481,242,951,5241,156,548,1511,009,847,4131,242,076,2692,167,471,6682,029,703,6591,112,733,8021,214,810,5241,050,165,4261,018,358,696660,419,604
Net income
-74m
L
33,821,40050,321,043134,800,571217,858,676244,104,839272,714,180523,344,976481,011,146577,397,433695,083,054575,049,108452,107,589533,575,372571,449,518486,783,623364,708,684425,939,565234,404,162416,691,942-74,065,657
CFO
225m
-51.00%
47,481,05657,552,51188,363,104194,321,168174,405,160238,134,139228,591,711398,595,751347,413,924465,004,184504,870,454396,861,456380,724,354485,173,510665,826,611415,837,437464,629,521389,820,900460,197,296225,487,183
Dividend
Jul 04, 20240.15 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and markets genetic engineering and related drugs in the People's Republic of China and internationally. The company's finished formulations includes temozolomide; arsenic trioxide; lenalidomide; docetaxel; paclitaxel; filgrastim Recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; ciclosporin; mycophenolate mofetil dispersible; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin (salmon); paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is based in Beijing, the People's Republic of China.
IPO date
Sep 09, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT